Your browser doesn't support javascript.
loading
Interaction between KDELR2 and HSP47 as a Key Determinant in Osteogenesis Imperfecta Caused by Bi-allelic Variants in KDELR2.
van Dijk, Fleur S; Semler, Oliver; Etich, Julia; Köhler, Anna; Jimenez-Estrada, Juan A; Bravenboer, Nathalie; Claeys, Lauria; Riesebos, Elise; Gegic, Sejla; Piersma, Sander R; Jimenez, Connie R; Waisfisz, Quinten; Flores, Carmen-Lisset; Nevado, Julian; Harsevoort, Arjan J; Janus, Guus J M; Franken, Anton A M; van der Sar, Astrid M; Meijers-Heijboer, Hanne; Heath, Karen E; Lapunzina, Pablo; Nikkels, Peter G J; Santen, Gijs W E; Nüchel, Julian; Plomann, Markus; Wagener, Raimund; Rehberg, Mirko; Hoyer-Kuhn, Heike; Eekhoff, Elisabeth M W; Pals, Gerard; Mörgelin, Matthias; Newstead, Simon; Wilson, Brian T; Ruiz-Perez, Victor L; Maugeri, Alessandra; Netzer, Christian; Zaucke, Frank; Micha, Dimitra.
Afiliação
  • van Dijk FS; Expert Center for Adults with Osteogenesis Imperfecta, Isala Hospital, 10400 Zwolle, the Netherlands; Department of Clinical Genetics, University Medical Center Groningen, 30001 Groningen, the Netherlands; North West Thames Regional Genetics Service, London North West Health Care University NHS Trus
  • Semler O; Department of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50931, Germany; Center for Rare Diseases, University Hospital Cologne, University of Cologne, Cologne 50931, Germany.
  • Etich J; Dr. Rolf M. Schwiete Research Unit for Osteoarthritis, Orthopaedic University Hospital Friedrichsheim gGmbH, Frankfurt/Main 60528, Germany.
  • Köhler A; Center for Biochemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50931, Germany.
  • Jimenez-Estrada JA; Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM), CSIC-UAM, Madrid 28029, Spain.
  • Bravenboer N; Department of Clinical Chemistry, Amsterdam Movement Sciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Claeys L; Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081BT, the Netherlands.
  • Riesebos E; Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081BT, the Netherlands.
  • Gegic S; Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081BT, the Netherlands.
  • Piersma SR; Department of Medical Oncology, Cancer center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Jimenez CR; Department of Medical Oncology, Cancer center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Waisfisz Q; Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081BT, the Netherlands.
  • Flores CL; Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM), CSIC-UAM, Madrid 28029, Spain.
  • Nevado J; Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), ISCIII, Madrid 28029, Spain; Institute of Medical & Molecular Genetics (INGEMM), Hospital Universitario La Paz-IdiPaz-Universidad Autonóma de Madrid, Madrid 28046, Spain.
  • Harsevoort AJ; Expert Center for Adults with Osteogenesis Imperfecta, Isala Hospital, 10400 Zwolle, the Netherlands.
  • Janus GJM; Expert Center for Adults with Osteogenesis Imperfecta, Isala Hospital, 10400 Zwolle, the Netherlands.
  • Franken AAM; Expert Center for Adults with Osteogenesis Imperfecta, Isala Hospital, 10400 Zwolle, the Netherlands.
  • van der Sar AM; Department of Medical Microbiology and Infection Control, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Meijers-Heijboer H; Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081BT, the Netherlands.
  • Heath KE; Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), ISCIII, Madrid 28029, Spain; Institute of Medical & Molecular Genetics (INGEMM), Hospital Universitario La Paz-IdiPaz-Universidad Autonóma de Madrid, Madrid 28046, Spain; Skeletal Dysplasia Multidisciplinary Unit (UMDE), Hosp
  • Lapunzina P; Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), ISCIII, Madrid 28029, Spain; Institute of Medical & Molecular Genetics (INGEMM), Hospital Universitario La Paz-IdiPaz-Universidad Autonóma de Madrid, Madrid 28046, Spain.
  • Nikkels PGJ; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Santen GWE; Department of Clinical Genetics, Leiden University Medical Centre, Leiden, the Netherlands.
  • Nüchel J; Center for Biochemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50931, Germany.
  • Plomann M; Center for Biochemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50931, Germany.
  • Wagener R; Center for Biochemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50931, Germany; Center for Molecular Medicine Cologne, University of Cologne, Cologne 50931, Germany.
  • Rehberg M; Department of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50931, Germany.
  • Hoyer-Kuhn H; Department of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50931, Germany.
  • Eekhoff EMW; Department of Internal Medicine Section Endocrinology, Amsterdam Movement Sciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Pals G; Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081BT, the Netherlands.
  • Mörgelin M; Colzyx AB, Medicon Village, Lund 22381, Sweden.
  • Newstead S; Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK.
  • Wilson BT; North West Thames Regional Genetics Service, London North West Health Care University NHS Trust, Harrow HA1 3UJ, UK; Biosciences Institute, Newcastle University, International Centre for Life, Newcastle upon Tyne NE1 3BZ, UK.
  • Ruiz-Perez VL; Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM), CSIC-UAM, Madrid 28029, Spain; Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), ISCIII, Madrid 28029, Spain; Institute of Medical & Molecular Genetics (INGEMM), Hospital Universitario La Paz-IdiPaz-Universidad A
  • Maugeri A; Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081BT, the Netherlands.
  • Netzer C; Center for Rare Diseases, University Hospital Cologne, University of Cologne, Cologne 50931, Germany; Institute of Human Genetics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50931, Germany.
  • Zaucke F; Dr. Rolf M. Schwiete Research Unit for Osteoarthritis, Orthopaedic University Hospital Friedrichsheim gGmbH, Frankfurt/Main 60528, Germany.
  • Micha D; Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081BT, the Netherlands. Electronic address: d.micha@amsterdamumc.nl.
Am J Hum Genet ; 107(5): 989-999, 2020 11 05.
Article em En | MEDLINE | ID: mdl-33053334
ABSTRACT
Osteogenesis imperfecta (OI) is characterized primarily by susceptibility to fractures with or without bone deformation. OI is genetically heterogeneous over 20 genetic causes are recognized. We identified bi-allelic pathogenic KDELR2 variants as a cause of OI in four families. KDELR2 encodes KDEL endoplasmic reticulum protein retention receptor 2, which recycles ER-resident proteins with a KDEL-like peptide from the cis-Golgi to the ER through COPI retrograde transport. Analysis of patient primary fibroblasts showed intracellular decrease of HSP47 and FKBP65 along with reduced procollagen type I in culture media. Electron microscopy identified an abnormal quality of secreted collagen fibrils with increased amount of HSP47 bound to monomeric and multimeric collagen molecules. Mapping the identified KDELR2 variants onto the crystal structure of G. gallus KDELR2 indicated that these lead to an inactive receptor resulting in impaired KDELR2-mediated Golgi-ER transport. Therefore, in KDELR2-deficient individuals, OI most likely occurs because of the inability of HSP47 to bind KDELR2 and dissociate from collagen type I. Instead, HSP47 remains bound to collagen molecules extracellularly, disrupting fiber formation. This highlights the importance of intracellular recycling of ER-resident molecular chaperones for collagen type I and bone metabolism and a crucial role of HSP47 in the KDELR2-associated pathogenic mechanism leading to OI.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteogênese Imperfeita / Osso e Ossos / Colágeno Tipo I / Proteínas de Transporte Vesicular / Proteínas de Choque Térmico HSP47 Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Am J Hum Genet Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteogênese Imperfeita / Osso e Ossos / Colágeno Tipo I / Proteínas de Transporte Vesicular / Proteínas de Choque Térmico HSP47 Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Am J Hum Genet Ano de publicação: 2020 Tipo de documento: Article